Paul A. Bethel, Lai Chun Chan, Katie Cooper, Gareth J. Ensor, Jerry Evarts, Rustam Garrey, J. Gair Ford, Daniel Harding, Shaun Hughes, Lucy Jackson, Michael Golden*, Kirsty Millard, Andrew Phillips, Andrew Robbins, David Short, Alex Telford and David T. E. Whittaker,
{"title":"Development of Commercial Manufacturing Processes for Acalabrutinib","authors":"Paul A. Bethel, Lai Chun Chan, Katie Cooper, Gareth J. Ensor, Jerry Evarts, Rustam Garrey, J. Gair Ford, Daniel Harding, Shaun Hughes, Lucy Jackson, Michael Golden*, Kirsty Millard, Andrew Phillips, Andrew Robbins, David Short, Alex Telford and David T. E. Whittaker, ","doi":"10.1021/acs.oprd.2c00304","DOIUrl":null,"url":null,"abstract":"<p >The development of processes to produce the Bruton tyrosine kinase inhibitor, acalabrutinib <b>1</b>, has resulted in improvements to the yield, cycle time, and operability, to realize a robust commercial manufacturing process. A highly accelerated clinical program meant that numerous key process challenges had to be resolved in a short timeframe. Issues are discussed, such as the uncontrolled epimerization of a chiral center and the control of the acalabrutinib <b>1</b> crystallization step, which was prone to oiling. Specifically, work to understand the complex polymorph landscape of a key intermediate (to facilitate resolution of a filtration issue) is described.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"26 12","pages":"3303–3311"},"PeriodicalIF":3.1000,"publicationDate":"2022-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Process Research & Development","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.oprd.2c00304","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0
Abstract
The development of processes to produce the Bruton tyrosine kinase inhibitor, acalabrutinib 1, has resulted in improvements to the yield, cycle time, and operability, to realize a robust commercial manufacturing process. A highly accelerated clinical program meant that numerous key process challenges had to be resolved in a short timeframe. Issues are discussed, such as the uncontrolled epimerization of a chiral center and the control of the acalabrutinib 1 crystallization step, which was prone to oiling. Specifically, work to understand the complex polymorph landscape of a key intermediate (to facilitate resolution of a filtration issue) is described.
期刊介绍:
The journal Organic Process Research & Development serves as a communication tool between industrial chemists and chemists working in universities and research institutes. As such, it reports original work from the broad field of industrial process chemistry but also presents academic results that are relevant, or potentially relevant, to industrial applications. Process chemistry is the science that enables the safe, environmentally benign and ultimately economical manufacturing of organic compounds that are required in larger amounts to help address the needs of society. Consequently, the Journal encompasses every aspect of organic chemistry, including all aspects of catalysis, synthetic methodology development and synthetic strategy exploration, but also includes aspects from analytical and solid-state chemistry and chemical engineering, such as work-up tools,process safety, or flow-chemistry. The goal of development and optimization of chemical reactions and processes is their transfer to a larger scale; original work describing such studies and the actual implementation on scale is highly relevant to the journal. However, studies on new developments from either industry, research institutes or academia that have not yet been demonstrated on scale, but where an industrial utility can be expected and where the study has addressed important prerequisites for a scale-up and has given confidence into the reliability and practicality of the chemistry, also serve the mission of OPR&D as a communication tool between the different contributors to the field.